Media & Resources

The International AIDS Vaccine Initiative (IAVI) applauds U.S. Secretary of State Hillary Clinton’s powerful, comprehensive speech on lesbian, gay, bisexual and transgender (LGBT) rights at the United Nations Human Rights Council in Geneva on December 6.  “Some have suggested that gay rights and human rights are separate and distinct,” Secretary Clinton said, “but in fact…

On this World AIDS Day, IAVI remembers the women, men and children who have lost their lives to AIDS. We also look ahead to the day when people no longer die because of AIDS, when there are no new cases of HIV, when people no longer experience stigma and discrimination simply because they are living…

NEW YORK, NOVEMBER 1, 2011—The International AIDS Vaccine Initiative (IAVI) announces the appointment to its Board of Directors of Mary Tydings, a Managing Director at Russell Reynolds Associates, one of the world’s largest executive recruiting and assessment firms. Tydings joins a diverse group of 16 directors from 10 countries with backgrounds in finance, vaccinology, international…

The International AIDS Vaccine Initiative (IAVI) congratulates the sponsors of the RTS,S Phase III efficacy trial, who published yesterday initial results showing that the vaccine candidate reduced the risk of clinical malaria and severe malaria by 56% and 47%, respectively, among children aged 5-17 months over the first year following vaccination. This success demonstrates the…

NEW YORK, NY, LA JOLLA and SOUTH SAN FRANCISCO, CA, SEATTLE, WA, August 17, 2011 — A team of researchers at and associated with the International AIDS Vaccine Initiative (IAVI), The Scripps Research Institute, the biotechnology company Theraclone Sciences and Monogram Biosciences Inc., a LabCorp company, report in the current issue of Nature the isolation of…

Flexible, agile and generous funding structures needed to ensure  development and delivery of lifesaving new options for HIV prevention ROME July 19, 2011—In the last year, promising trial results and critical scientific breakthroughs have changed the HIV prevention landscape, providing new opportunities for both a broader response to the epidemic with new prevention options and…

The International AIDS Vaccine Initiative (IAVI) welcomes news of the positive results of the Partners PrEP study, a multinational clinical study evaluating the daily use of oral antiretroviral drugs to prevent HIV acquisition, a strategy known as pre-exposure prophylaxis (PrEP).  Partners PrEP involved 4,758 heterosexual HIV discordant couples, in which one partner is HIV positive,…

NEW YORK, July 7, 2011—The International AIDS Vaccine Initiative (IAVI) is pleased to announce the appointment of Margaret (Margie) McGlynn as President and Chief Executive Officer. McGlynn, who has been a member of the IAVI Board of Directors since July 2010, replaces Seth Berkley, IAVI’s Founding President and CEO. She will work with the Board…